Madison Cook, AUD | |
1245 Kuala St Ste 104, Pearl City, HI 96782-3900 | |
(808) 400-1409 | |
Not Available |
Full Name | Madison Cook |
---|---|
Gender | Female |
Speciality | Audiologist |
Location | 1245 Kuala St Ste 104, Pearl City, Hawaii |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1720865934 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
231H00000X | Audiologist | 254 (Hawaii) | Primary |
Mailing Address | Practice Location Address |
---|---|
Madison Cook, AUD 1245 Kuala St Ste 104, Pearl City, HI 96782-3900 Ph: (808) 400-1409 | Madison Cook, AUD 1245 Kuala St Ste 104, Pearl City, HI 96782-3900 Ph: (808) 400-1409 |
News Archive
Life Technologies Corporation and the German Cancer Research Center (Deutsches Krebsforschungszentrum or DKFZ) today announced their collaboration to create the National High-Throughput Sequencing Center. This exclusive partnership will create the largest sequencing facility in Germany and the first national sequencing center in Europe dedicated to systems biology.
An international team led by human genetic researchers at the University of British Columbia and Vancouver Coastal Health has identified the latest gene associated with typical late-onset Lewy body Parkinson's disease (PD), with the help of a Canadian Mennonite family of Dutch-German-Russian ancestry.
The Senate Health, Education, Labor and Pensions Committee has moved to Thursday the confirmation hearing for Margaret Hamburg, President Obama's pick for FDA commissioner, citing the need to address the H1N1 influenza outbreak, the Wall Street Journal reports.
3D cell culture company Reinnervate Ltd today announced partnerships with two oncology-focussed CRO's to offer 3D tumour cell screening services. The CROs, Oncotest GmbH (Freiburg, Germany) and SBH Sciences (Natick, MA, USA) will both offer a new service for clients wishing to try out cancer 3D cell culture screening for the first time or who wish to evaluate new tumour types in their models.
Affymetrix, Inc., today reported its operating results for the third quarter of 2012. Total revenue for the quarter was $79.6 million, including approximately $17.6 million in revenue from eBioscience during the third quarter of 2012. This compares to total revenue of $64.0 million for the same period of 2011.
› Verified 8 days ago